Lipoprotein-associated phospholipase A2 independently predicts the angiographic diagnosis of coronary artery disease and coronary death

American Heart Journal

Volumn 152, Issue 5, 2006, Pages 997-1003

  May, Heidi T ^a   Horne, Benjamin D ^a   Anderson, Jeffrey L ^a,b   Wolfert, Robert L ^c   Muhlestein, Joseph B ^a,b   Renlund, Dale G ^a,b   Clarke, Jessica L ^a   Kolek, Matthew J ^a   Bair, Tami L ^a   Pearson, Robert R ^a   Sudhir, Krishnankutty ^c   Carlquist, John F ^a,b  

^a LDS HOSPITAL   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c diaDexus Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PHOSPHOLIPASE A2;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DISEASE ASSOCIATION; ENZYME BLOOD LEVEL; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; REGISTER; RISK ASSESSMENT;

CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; PHOSPHOLIPASES A; PREDICTIVE VALUE OF TESTS;

EID: 33750370865     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2006.01.011     Document Type: Article

References (23)

1. American Heart Association. Heart disease and stroke statistical update (2004), American Heart Association, Dallas (Tex)
2. Anderson K.M., Odell P.M., Wilson P.W.F., et al. Cardiovascular disease risk profiles. Am Heart J 121 (1991) 293-298
3. Khot M.B., Bajzer C.T., Sapp S.K., et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 290 (2003) 898-904
4. Ridker P.M., Rifai N., Rose L., et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347 (2002) 1557-1565
5. Ridker P.M., Cushman M., Stampfer M.J., et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently health men. N Engl J Med 336 (1997) 973-979
6. Albert M.A., Glynn R.J., and Ridker P.M. Plasma concentration of C-reactive protein and the calculated Framingham coronary heart disease risk score. Circulation 108 (2003) 161-165
7. Ridker P.M., and Cook N. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores. Circulation 109 (2004) 1955-1959
8. Bogaty P., Brophy J.M., Boyer L., et al. Fluctuating inflammatory markers in patients with stable ischemic heart disease. Arch Intern Med 165 (2005) 221-226
9. 2 as an independent predictor of coronary heart disease. N Engl J Med 343 (2000) 1148-1155
10. 2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population. Circulation 110 (2004) 1903-1908
11. 2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 109 (2004) 837-842
12. 2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J 26 (2005) 137-144
13. 2: a potential new risk factor for coronary artery disease and a therapeutic target. Curr Opin Pharmacol 1 (2001) 121-125
14. 2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J 3338 Pt 2 (1999) 479-487
15. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340 (1999) 115-126
16. 2 diminishes the death-inducing effects of oxidized LDL on human monocyte-macrophages. FEBS Lett 505 (2001) 357-363
17. Rexrode K.M., Lee I.M., Cook N.R., et al. Baseline characteristics of participants in the women's health study. J Women's Health Gend Based Med 9 (2000) 19-27
18. Anonymous. Myocardial infarction and mortality in the Coronary Artery Surgery Study (CASS) randomized trial. N Engl J Med 310 (1984) 750-758
19. 2, platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis 150 (2000) 413-419
20. Clarke J.L., Anderson J.L., Carlquist J.F., et al. Comparison of differing C-reactive protein assay methods and their impact on cardiovascular risk assessment. Am J Cardiol 95 (2005) 155-158
21. Ridker P.M., Glynn R.J., and Hennekens C.H. C-Reactive protein adds to the predictive value of total HDL cholesterol in determining risk of first myocardial infarction. Circulation 97 (1998) 2007-2011
22. Ridker P.M., Rifai N., Pfeffer M.A., et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 100 (1999) 230-235
23. 2: a potential new risk factor for coronary artery disease and a therapeutic target. Curr Opin Pharmacol 1 (2001) 121-125